Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study

Men who take statins are less likely to die from prostate cancer than those who don't

2013-05-02

(Press-News.org) SEATTLE – Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center. The findings are published online today in The Prostate. The study, led by Janet L. Stanford, Ph.D., co-director of the Prostate Cancer Research Program and a member of the Hutchinson Center's Public Health Sciences Division, followed about 1,000 Seattle-area prostate cancer patients. Approximately 30 percent of the study participants reported using statin drugs to control their cholesterol. After a mean follow-up of almost eight years, the researchers found that the risk of death from prostate cancer among statin users was 1 percent as compared to 5 percent for nonusers. "If the results of our study are validated in other patient cohorts with extended follow-up for cause-specific death, an intervention trial of statin drugs in prostate cancer patients may be justified," Stanford said. "While statin drugs are relatively well tolerated with a low frequency of serious side effects, they cannot be recommended for the prevention of prostate cancer-related death until a preventive effect on mortality from prostate cancer has been demonstrated in a large, randomized, placebo-controlled clinical trial," said first author Milan S. Geybels, M.Sc., formerly a researcher in Stanford's group who is now based at Maastricht University in The Netherlands. The study is unique in that most prior research of the impact of statin use on prostate cancer outcomes has focused on biochemical recurrence – a rising PSA level – and not prostate cancer-specific mortality. "Very few studies of statin use in relation to death from prostate cancer have been conducted, possibly because such analyses require much longer follow-up for the assessment of this prostate cancer outcome," Geybels said. The potential biological explanation behind the association between statin use and decreased mortality from prostate cancer may be related to cholesterol- and non-cholesterol-mediated mechanisms. An example of the former: When cholesterol is incorporated into cell membranes, these "cholesterol-rich domains" play a key role in controlling pathways associated with survival of prostate cancer cells. An example of the latter: Statin drugs inhibit an essential precursor to cholesterol production called mevalonate. Lower levels of mevalonate may reduce the risk of fatal prostate cancer. "Prostate cancer is an interesting disease for which secondary prevention, or preventing poor long-term patient outcomes, should be considered because it is the most common cancer among men in developed countries and the second leading cause of cancer-related deaths," Geybels said. "While many prostate cancer patients have indolent, slow-growing tumors, others have aggressive tumors that may recur or progress to a life-threatening disease despite initial therapy with radiation or surgery. Therefore, any compound that could stop or slow the progression of prostate cancer would be beneficial," he said. ###The National Cancer Institute, a grant from the Dutch Cancer Society and additional support from Fred Hutchinson Cancer Research Center and the Prostate Cancer Foundation funded the research. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit http://www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube. END

ELSE PRESS RELEASES FROM THIS DATE:

New genetic clues to breast and ovarian cancer

2013-05-02

A major international study involving a Simon Fraser University scientist has found that sequence differences in a gene crucial to the maintenance of our chromosomes' integrity predispose us to certain cancers. Angela Brooks-Wilson, an associate professor in SFU's biomedical physiology and kinesiology department and a Distinguished Scientist at the BC Cancer Agency, is one of more than 600 scientists globally who contributed to this study. Published in the March 27, 2013 online issue of the science journal Nature Genetics, the study is called Multiple independent ...

Genetic factor predicts success of weight-loss surgery

2013-05-02

More than one-third of adults in the United States are obese, and some of these individuals undergo gastric bypass surgery to shed the extra pounds. A genome-wide association study published by Cell Press May 2nd in The American Journal of Human Genetics reveals that the amount of weight loss after this surgery can be predicted in part by a DNA sequence variation found on chromosome 15. The findings explain why the success of gastric bypass surgery varies so widely and could help clinicians identify those who would benefit the most from this type of surgery. "Surgery ...

Kids with brains that under-react to painful images

2013-05-02

When children with conduct problems see images of others in pain, key parts of their brains don't react in the way they do in most people. This pattern of reduced brain activity upon witnessing pain may serve as a neurobiological risk factor for later adult psychopathy, say researchers who report their findings in the Cell Press journal Current Biology on May 2. That's not to say that all children with conduct problems are the same, or that all children showing this brain pattern in young life will become psychopaths. The researchers emphasize that many children with ...

Bonding with your virtual self may alter your actual perceptions

2013-05-02

When people create and modify their virtual reality avatars, the hardships faced by their alter egos can influence how they perceive virtual environments, according to researchers. A group of students who saw that a backpack was attached to an avatar that they had created overestimated the heights of virtual hills, just as people in real life tend to overestimate heights and distances while carrying extra weight, according to Sangseok You, a doctoral student in the school of information, University of Michigan. "You exert more of your agency through an avatar when ...

An anarchic region of star formation

2013-05-02

NGC 6559 is a cloud of gas and dust located at a distance of about 5000 light-years from Earth, in the constellation of Sagittarius (The Archer). The glowing region is a relatively small object, just a few light-years across, in contrast to the one hundred light-years and more spanned by its famous neighbour, the Lagoon Nebula (Messier 8, eso0936 - http://www.eso.org/public/news/eso0936/). Although it is usually overlooked in favour of its distinguished companion, NGC 6559 has the leading role in this new picture. The gas in the clouds of NGC 6559, mainly hydrogen, is ...

Adult cells transformed into early-stage nerve cells, bypassing the pluripotent stem cell stage

2013-05-02

MADISON, Wis. — A University of Wisconsin-Madison research group has converted skin cells from people and monkeys into a cell that can form a wide variety of nervous-system cells — without passing through the do-it-all stage called the induced pluripotent stem cell, or iPSC. Bypassing the ultra-flexible iPSC stage was a key advantage, says senior author Su-Chun Zhang, a professor of neuroscience and neurology. "IPSC cells can generate any cell type, which could be a problem for cell-based therapy to repair damage due to disease or injury in the nervous system." In ...

Gene variant appears to predict weight loss after gastric bypass

2013-05-02

Massachusetts General Hospital (MGH) researchers have identified a gene variant that helps predict how much weight an individual will lose after gastric bypass surgery, a finding with the potential both to guide treatment planning and to facilitate the development of new therapeutic approaches to treating obesity and related conditions like diabetes. The report receiving advance online publication in The American Journal of Human Genetics is the first to identify genetic predictors of weight loss after bariatric surgery. "We know now that bypass surgery works not by ...

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

2013-05-02

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved. Prof Mario Campone, Principal Investigator ...

Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence

2013-05-02

Lugano-CH, Brussels-BE, 2 May 2013 -- A test that measures the expression levels of 58 genes in oestrogen receptor-positive breast cancers can effectively differentiate between patients who are at higher and lower risk for having their cancer recur elsewhere in the body more than five years after diagnosis, researchers report. The new findings show that better individual risk prediction for women with these cancers is getting nearer, says study author Prof Michael Gnant from the Medical University of Vienna, Austria. Prof Gnant reported the findings at the 5th IMPAKT ...

Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer

2013-05-02

Lugano-CH, Brussels-BE, 2 May 2013 -- A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment. The promising new findings will likely benefit the many women with oestrogen-receptor positive breast cancer whose cancer recurs more than five years after diagnosis, researchers told the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents ...